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The research paradigm of using human genetic variation
to unequivocally, causally, and directionally link a speciﬁc
gene with a speciﬁc phenotype, trait, or disease has yielded
extraordinary discoveries at an accelerating pace (1–3). In-
creasingly, this approach has been of interest as a way of
“validating” targets for novel therapeutic intervention (4). For
example, the promising low-density lipoprotein cholesterol
(LDL-C)–lowering drug target PCSK9 was initially linked
to LDL metabolism by the discovery of gain-of-function
mutations causing elevated LDL-C (5). Subsequently, it
was validated as a drug target by the discovery that loss-
of-function mutations cause low LDL-C (6) and markedly
protect against the development of coronary heart disease
(7,8). PCSK9 inhibitors are now in late-stage clinical
development and have superior LDL-lowering capacity with
an apparent high margin of safety and tolerability (9). The
story of PCSK9 has been repeatedly held up as a prime
example of the power of human genetics to identify and
validate new therapeutic targets, and many efforts areSee page 2121underway to duplicate this scenario for other unmet medical
needs by searching for both common and rare genetic variants
that are compellingly associated with the disease of interest.
However, a key aspect of the PCSK9 storydand indeed
the overall approach of using human genetics to validate new
therapeutic targetsdis related to the ability of human ge-
netics to not only inform potential efﬁcacy but also safety of
targeting a particular molecule. Studies of individuals car-
rying loss-of-function variants in PCSK9 revealed no*Editorials published in the Journal of the American College of Cardiology reﬂect the
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activity (7). The approach of starting with 1 or more variants
in a speciﬁc gene and asking broadly what phenotypes are
associated with those variantsda so-called “phenome
scan”dhas been less-commonly reported in the literature,
perhaps due to the fact that the bioinformatic methodology
involved has only recently been validated (10). Phenome-
wide association studies (PheWAS) have the potential to
provide critical information on pleiotropic and perhaps un-
expected effects associated with variation in genes of interest
(11,12). In fact, a number of groups have recently elucidated
unexpected phenotypic associations with certain genetic
variants found in genome-wide association studies for other
traits (13–16). For example, a recent PheWAS analysis of 81
single-nucleotide polymorphisms (SNPs) associated with
platelet count and volume revealed previously unknown as-
sociations with myocardial infarction (MI), autoimmune,
and hematologic disorders (15).
In this issue of the Journal, Stender et al. (17) highlight
the pleiotropic effects of functional variants in 2 related
genes, ATP-binding cassette, sub-family G, member 5
(ABCG5) and ABCG8, on MI and gallstone disease,
2 seemingly unrelated diseases. These 2 genes each encode
half of the ABCG5/8, which is expressed in enterocytes
and hepatocytes and plays a critical role in the efﬂux of
cholesterol into the intestinal lumen or the bile, respectively
(18–20). Stender et al. (17) report that several variants in the
ABCG5/8 genes are shown to affect the risk of MI and
gallstone disease in opposite directions, presumably based
on the transporter’s role inﬂuencing both LDL metabolism
and biliary cholesterol metabolism.
The authors chose to address this question because variants
in ABCG5/8 had, in different studies and cohorts, been
previously associated with MI (21) and gallstones (22), and
also because the physiology of ABCG5/8 is consistent
with its inﬂuencing both LDL-C levels (a risk factor for MI)
(23) and biliary cholesterol (a risk factor for gallstones)
(24,25). To this end, the authors made use of 3 Danish co-
horts totaling >60,000 subjects including >5,500 with
MI and >3,000 with symptomatic gallstone disease. They
genotyped 5 common nonsynonymous and 1 known func-
tional intronic variant in ABCG5/8 and calculated a
weighted genotype score based on their percentage re-
ductions in LDL-C compared to the reference genotypes. As
expected, the genotype score was signiﬁcantly associated with
lower LDL-C levels. The major ﬁnding of the study was that
genotype score was related to MI and gallstone disease in
opposite directions: the higher the score was, the lower the
risk of MI was, but the higher the risk of symptomatic
gallstone disease was.
The best studied of the 6 variants was the D19H variant
in ABCG8, a known gain-of-function variant that had
previously been shown to be a monogenic determinant of
gallstone disease risk (25,26). Importantly, the relationship
of genotype score to MI and gallstone disease persisted when
a genotype score was calculated independently of the D19H
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2130variant. Overall, these ﬁndings are consistent with geneti-
cally manipulated animal studies (27–29), and support a
model that gain of function of ABCG5/8 in humans in-
creases cholesterol ﬂux from hepatocytes to bile, thus directly
increasing the lithogenicity of bile while indirectly reducing
plasma LDL-C and risk of MI.
These results reinforce an important paradigm, namely
that single gene variants may have multiple effects on
seemingly unrelated phenotypes or diseases. This principle
has important implications for using human genetics for
validation of new therapeutic targets. For example, based
on these data, one may anticipate that a therapeutic inter-
vention to up-regulate expression or function of ABCG5/8
would reduce LDL-C and risk of MI, but increase risk of
gallstone disease. Importantly, the ability to detect the as-
sociation of ABCG5/8 variants with gallstone disease re-
quired a very large sample size of subjects for whom data on
gallstone disease were available. Depending on the trait or
disease, an appropriately phenotyped sample of the necessary
size will not always be available to address such questions.
Nevertheless, as the interest in human genetics for target
validation continues to grow, the importance of broad
phenome scans to address potential safety issues will increase
as well. The goal is to generate conﬁdence that perturbation
of a target’s function will not lead to “on-target” adverse
effects that would compromise its value as a therapeutic
target. Large-scale genotyping and sequencing of potential
targets in very large cohorts that have been phenotyped in
great detail will be needed in order to perform the necessary
phenome scans to provide conﬁdence that a target is ad-
equately safe to merit a full-scale developmental program.
Stender et al. (17) have provided a compelling and easily
understood example of the clinical “catch-22” that will likely
be associated with many human genetic variants and, if
discovered, will impact on drug discovery decisions.Reprint requests and correspondence: Dr. Daniel J. Rader,
University of Pennsylvania, 3400 Civic Center Boulevard, 11-125
SCTR, Philadelphia, Pennsylvania 19104-6160. E-mail: rader@
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